There’s never been a better time to Buy BC and support local growers, producers and the food we love right here in BC.
Explore Buy BC products

Skip to main content
Skip to main navigation
Accessibility Statement

Limited coverage criteria – naproxen EC

Last updated on March 19, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Learn more or log in

Return to Special Authority drug list

Generic name	naproxen
Strength & form	250 mg/375 mg/500 mg enteric-coated tablet

Special Authority criteria	Approval period
For the treatment of patients who have a: Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, or lupus OR Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen	Indefinite

Special Authority criteria

Approval period

For the treatment of patients who have a:

Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, or lupus

Treatment failure on optimal doses of, or intolerance to, both ibuprofen and naproxen

Indefinite

Practitioner exemptions

Practitioners in the following specialty are not required to submit a Special Authority request form for coverage:

Pediatrics
Pediatric cardiology
Pediatric general surgery
Physical medicine and rehabilitation
Rheumatology

Special notes

Treatment failure on or intolerance to the specific medications listed in the above criteria is required

Special Authority request form(s)

Log in to eForms
HLTH 5328 – General Special Authority request (PDF, 656KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics